Related Experiment Video
Updated: Jun 23, 2025
NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode
Published on: June 4, 2021
TRAF6 Inhibitors from Marine Compound Library: Pharmacophore, Virtual Screening, Fragment Replacement, ADMET, and
Xuexuan Wu1, Saiyi Zhong2, Nan Zhou1
1The First Clinical College, Guangdong Medical University, Zhanjiang 524023, China.
Abstract:
TRAF6 is an E3 ubiquitin ligase that plays a crucial role in cell signaling. It is known that MMP is involved in tumor metastasis, and TRAF6 induces MMP-9 expression by binding to BSG. However, inhibiting TRAF6's ubiquitinase activity without disrupting the RING domain is a challenge that requires further research. To address this, we conducted computer-based drug screening to identify potential TRAF6 inhibitors. Using a ligand-receptor complex pharmacophore based on the inhibitor EGCG, known for its anti-tumor properties, we screened 52,765 marine compounds. After the molecular docking of 405 molecules with TRAF6, six compounds were selected for further analysis. By replacing fragments of non-binding compounds and conducting second docking, we identified two promising molecules, CMNPD9212-16 and CMNPD12791-8, with strong binding activity and favorable pharmacological properties. ADME and toxicity predictions confirmed their potential as TRAF6 inhibitors. Molecular dynamics simulations showed that CMNPD12791-8 maintained a stable structure with the target protein, comparable to EGCG. Therefore, CMNPD12791-8 holds promise as a potential inhibitor of TRAF6 for inhibiting tumor growth and metastasis.
Insights
Researchers identified novel marine compounds as potential inhibitors of TRAF6, a key protein in tumor metastasis. These compounds show promise for developing new anti-cancer therapies targeting tumor growth and spread.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- TRAF6 (TNF receptor-associated factor 6) is an E3 ubiquitin ligase critical for cell signaling pathways.
- TRAF6 promotes tumor metastasis by inducing Matrix Metalloproteinase-9 (MMP-9) expression via binding to BSG.
- Targeting TRAF6's enzymatic activity presents a therapeutic challenge due to the need to preserve its RING domain.
Purpose of the Study:
- To identify novel inhibitors of TRAF6's ubiquitinase activity.
- To discover potential anti-cancer agents for inhibiting tumor growth and metastasis.
Main Methods:
- Computer-based drug screening of 52,765 marine compounds using a pharmacophore model based on EGCG.
- Molecular docking of selected compounds with TRAF6.
- Fragment-based drug design and secondary docking for optimization.
- ADME/Toxicity predictions and molecular dynamics simulations.
Main Results:
- Six compounds showed initial binding affinity to TRAF6.
- Two compounds, CMNPD9212-16 and CMNPD12791-8, exhibited strong binding and favorable pharmacological profiles.
- CMNPD12791-8 demonstrated stable interaction with TRAF6, similar to the known inhibitor EGCG.
Conclusions:
- CMNPD12791-8 is a promising candidate for a TRAF6 inhibitor.
- This compound holds potential for developing new therapeutic strategies against tumor metastasis.
